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Cutaneous Microdialysis as a Novel Means
of Continuously Stimulating Eccrine Sweat
Glands In Vivo
Caroline J. Morgan1, Peter S. Friedmann1, Martin K. Church1 and Geraldine F. Clough1
Previous studies of the pharmacological regulation of sweat gland function in humans have administered
agonists or antagonists systemically, by local intradermal injection or by iontophoresis. This has not allowed
prolonged or steady-state activation of sweat glands to be examined. In this study, we used the technique of
dermal microdialysis to administer pharmacological agents singly and in combination for up to 5 hours.
Muscarinic stimulation with pilocarpine nitrate (50 mg ml1 to 1.66 mg ml1) produced a sigmoid dose response
curve, with maximal sweating (measured as transepidermal water loss) (mean 70 g m2 hour1) after 15 minutes.
This was sustained at steady-state levels (55 g m2 hour1) until perfusion stopped. Perfusion with atropine
(0.003 mg ml1) reduced sweating below baseline and blocked pilocarpine-induced sweating completely.
Noradrenaline (0.005 mg ml1) induced much lower sweat rates than pilocarpine (56.871.62 g m2 hour1 vs
8.271.2 g m2 hour1, respectively, Po0.001) and this was unaffected by co-administration of atropine. This
method has made it possible to show that sweat glands are capable of sustaining near maximal activity for at
least 5 hours. The method has future application in investigation of conditions with disordered sweat gland
activity.
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INTRODUCTION
Human eccrine sweat glands have two major functions; first,
they are critically involved in thermoregulation, producing
sweat, the evaporation of which allows body cooling, and
second, they improve the grip of the palms and soles at times
of activity. Sweat production is under the control of the
sympathetic nervous system, but unusually, the post-gang-
lionic sudomotor fibers release acetylcholine as their main
neurotransmitter, acting on muscarinic receptors situated on
the secretory coil (Kurzen et al., 2004). The secretory coil also
has alpha and beta-adrenergic receptors. However, adren-
ergic receptor-induced sweat is only about 10% as copious as
that resulting from activation of cholinergic receptors (Sato,
1983).
Clinically abnormal sweat production can be due to an
alteration in the number, distribution or structure of sweat
glands, or to a problem with their innervation. The
pathophysiology of altered sweating in many disorders is
not fully understood. Although idiopathic hyperhidrosis can
be reduced by chemodenervation using botulinum A toxin,
the effect is temporary and the pathophysiology of excessive
sweating is uncertain. Similarly the understanding of
idiopathic generalized anhydrosis is poor.
Studies of the pharmacological control of sweat glands in
vivo have reported the introduction of agonists or antagonists
into the dermis by iontophoresis (Kato et al., 1999;
DiPasquale et al., 2003), skin prick, or intradermal injection
(Wolf and Maibach, 1974; Szabadi et al., 1980; Sato and
Sato, 1983) as single or repeated doses. Pharmacological
agents have also been given orally (Foster et al., 1970)
systemically or via intravenous or intra-arterial injection. The
disadvantage of all of these techniques is that they do not
allow continuous delivery of agonist or antagonist to the
sweat gland. Hence, the extended effects of steady-state drug
concentrations on sweat gland activity have been difficult to
explore.
Cutaneous microdialysis has been used previously for the
continuous local delivery of pharmacological agents under
minimally traumatic conditions to investigate cutaneous
vascular and neurogenic function (Schmelz et al., 1997;
Clough, 1999; Minson et al., 2001; Shibasaki and Crandall,
2001). The present study set out to re-examine some of the
previously defined aspects of sweat gland physiology using
microdialysis to deliver a muscarinic agonist (pilocarpine
nitrate) and antagonist (atropine sulfate) directly to the skin of
healthy volunteers and to investigate whether pharmacologi-
cal stimulation to sweat glands in vivo in this way can
provide a greater understanding of sweat gland activity.
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RESULTS
Transepidermal water loss (TEWL) measured at 20 minute
intervals during the 5 hours study did not differ significantly
at instrumented Ringer-perfused sites from that measured
in control skin at un-instrumented sites on the contra-
lateral forearm (P¼ 0.065). TEWL showed an initial small
increase during the first 20 minutes of Ringer perfusion,
but then fell rapidly to reach a steady-state value of
10.271.1 g m2 hour1, similar to that seen at control sites
(9.770.8 g m2 hour1) (Figure 1a). As the instrumented sites
used in this initial validation study had been exposed to
topical local anesthetic cream (EMLA) for 1.5 hours before
probe insertion, a second series of measurements were made
to compare sweating rates at EMLA-treated and EMLA-free
uninstrumented skin sites. A similar, but not significant,
increase in TEWL was seen in uninstrumented skin treated
with EMLA cream compared to that at instrumented sites over
the first 20–40 minutes of measurement (Figure 1b).
Pilocarpine induced sweating
Blood pressure and resting pulse rate were unaffected by the
concentrations of pilocarpine used, nor was there evidence
of excessive salivation, tear secretion, or other systemic
cholinergic-mediated effects in any of the volunteers. An area
of erythema was visible in all volunteers along the length of
the pilocarpine-perfused probe at the higher concentrations
of pilocarpine used. There was no evidence of a wider
spreading neurogenic flare at any concentration.
Pilocarpine administered via the probe caused a concen-
tration-dependent increase in TEWL (Figure 2). At all
concentrations, the maximal effects of pilocarpine on TEWL
were seen within the first 20 minutes of perfusion. At the three
higher concentrations of pilocarpine, this initial increase was
followed by a decline in TEWL to reach a steady state of
approximately four times baseline, 90–120 minutes after the
start of perfusion (Figure 3). The steady-state values for TEWL
measured in the eight individuals in response to pilocarpine
are shown in Figure 2 together with the response of a further
six individuals to the higher concentration of pilocarpine
(1.66 mg ml1) used in study 2.
Effect of atropine on sweating induced by pilocarpine or
noradrenaline
Addition of atropine to the probe perfusate caused a
rapid reduction in pilocarpine-stimulated sweating to-
wards baseline levels (Po0.01). (Figure 3). Pilocarpine
had no effect on noradrenaline-induced sweating (data
not shown). However, atropine alone did cause a small
but significant reduction in steady-state TEWL to below
baseline levels (4.270.8 g m2 hour1, Po0.01). Both
the maximal and total sweating induced by noradrenaline
was significantly lower than that induced by pilocarpine
(max TEWL pilocarpine 56.871.62 g m2 hour1; noradrena-
line 8.271.2 g m2 hour1, Po0.001) (Figure 4). Addition
of noradrenaline to the pilocarpine probe perfusate
had little additional effect on maximum sweating
(51.372.39 g m2 hour1) (Figure 4).
DISCUSSION
Much of the previous work on sweat gland physiology and
pharmacology has involved the use of in vitro preparations of
isolated animal or human sweat glands (reviewed in K. Sato,
1983). Where in vivo studies have been performed, they
have generally investigated sweating responses to short-term
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Figure 1. TEWL measurements. (a) TEWL measured at 20 minutes intervals in
the skin directly above a microdialysis probe during 5 hours continuous
perfusion with Ringer’s solution at a rate of 5ml minute1 (closed squares) and
at a control uninstrumented skin site on the contralateral forearm (open
circles). (b) TEWL measured at 10 minutes intervals in uninstrumented skin at
control sites (open circles) and at sites treated with EMLA cream for 1.5 hours
before measurement of TEWL (closed circles) Data are mean7SEM, n¼ 8 and
n¼ 5, respectively.
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Figure 2. Concentration-dependent effects on steady-state TEWL in response
to pilocarpine nitrate (5 105 to 5 101 mg ml1) in Ringer’s solution.
TEWL was measured directly above each probe at 20 minutes intervals. Data
are mean7SEM for n¼8 healthy volunteers. Also shown on the graph is the
steady-state TEWL in response to pilocarpine nitrate (1.66 mg ml1) from a
further six volunteers from Study 2. The values for TEWL measured above
Ringer perfused probes in the steady state are represented as a dotted line.
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delivery of pharmacological agonists and antagonists by
iontophoresis or intradermal injection. In the present study,
we have used intradermal microdialysis to co-deliver agonists
and antagonists to the sweat glands over extended (5 hours)
periods in order to investigate sustained cholinergic and
adrenergic sweating in healthy human skin.
Pilocarpine delivered continuously to the skin via a
microdialysis probe caused a sustained, concentration-
dependent increase in sweating. The increase in TEWL was
maximal during the first two hours of the study for all
concentrations of pilocarpine. At the higher concentrations of
pilocarpine, this maximal increase in TEWL was followed
by a small but significant reduction in sweat production
suggesting a decline in gland sensitivity following extended
periods of agonist exposure. A reduction in sweat gland
activity was seen following repeated intradermal injection of
high doses of pilocarpine in human (Thaysen and Schwartz,
1955) and murine skin (Vilches et al., 1995). However, it is
difficult to follow the time course of eccrine sweating using
bolus injection or iontophoresis (Benarroch and Low, 1991;
Namer et al., 2004). Where agonists have been delivered
continuously, only maximal sweating rates have been
reported or sudomotor function has been followed for only
relatively short (30 minutes) periods of time (Shastry et al.,
2000; Bickel et al., 2002, 2004; Namer et al., 2004). Thus,
our data provide a novel insight into the effects of sustained
delivery and its consequences on sweat gland function. They
also reveal new information about the stamina of sweat
glands and their ability to sustain sweat production for many
hours.
Pilocarpine-induced sweating was significantly attenuated
by addition of the muscarinic blocker atropine to the probe
perfusate. This is consistent with other studies in which it has
been demonstrated that local modulation of cholinergic
activity can inhibit thermally induced sweat rate in humans
(Shibasaki and Crandall, 2001). Interestingly, the continuous
delivery of atropine sulfate alone to sweat glands also
reduced sweat gland activity below basal levels. This suggests
that under resting conditions, there is continuous muscarinic
sweat gland stimulation.
The role of noradrenaline in sweat production is unclear.
In the forearm, cholinergic sweating was much greater than
that induced by adrenergic stimulation. At steady state,
noradrenaline increased sweating by only 20% of that
induced by pilocarpine. This figure is similar to that
previously reported for adrenergic stimulation of sweat glands
(Foster et al., 1970; Szabadi et al., 1980; Sato and Sato, 1983)
following a single injection of agonist. It is interesting to note
that co-delivery of pilocarpine and noradrenaline caused less
sweating than pilocarpine alone. One possible explanation
for this is that sweat gland function is compromised by
noradrenaline-induced vasoconstriction resulting in a re-
duced supply of nutrients and water. If vasoconstriction was
limiting the delivery of essential nutrients and water to the
glands, it might be expected that the shape of the sweating
curves following stimulation by pilocarpine and pilocarpine
with noradrenaline would differ. We found no such
differences. Therefore, if vasoconstriction is affecting sweat
gland nutrient supply, it does not appear to be an absolute
rate-limiting step in sweat production. An alternative
explanation for the reduced noradrenaline-induced sweating
is enhanced sweat reabsorption in the sweat duct through
beta-adrenergic stimulation, this may lead to an imbalance in
primary sweat production and reabsorption (Sato, 1983).
Delivery and recovery of substances by microdialysis
have been extensively used to investigate tissue metabolism,
vascular and neurogenic function in a wide range of
physiological and pathophysiological conditions (Muller,
2000; Schmelz and Petersen, 2001; Clough and Church,
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Figure 3. Effect of muscarinic blockade on cholinergic stimulation of
sweating. Two microdialysis probes were initially perfused with pilocarpine
(1.66 mg ml1) and TEWL readings taken every 20 minutes for 2 hours (closed
symbols). The perfusate of one of the probes was then switched to one
containing pilocarpine (1.66 mg ml1) and atropine (0.003 mg ml1) (open
symbols) and TEWL readings continued at 20 minutes intervals for a further
3 hours. Atropine caused a significant reduction in TEWL (Po0.01, analysis of
variance). Data are mean7SEM for n¼3 healthy volunteers. Dotted line
represents unstimulated TEWL measured over Ringer-perfused microdialysis
probes (see Figure 1).
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Figure 4. Total sweating response. Total sweating response calculated from
the area under the TEWL curve AUC0–300 min during perfusion of the
microdialysis probes with either Ringer’s solution, pilocarpine (1.66 mg ml1),
noradrenaline (0.005 mg ml1), or pilocarpine and noradrenaline. Control
measurements were taken from the contralateral uninstrumented forearm.
Data are from eight healthy volunteers. Bar represents median value. NSD, no
significant difference.
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2002). In this study, it proved an effective method by which
known concentrations of agonists and antagonists could be
delivered relatively a-traumatically to the skin. The effective
concentration of these molecules reaching the tissue will
depend on the dialysis efficiency (Ed) of the microdialysis
membranes (Clough, 2005). However, whereas no estimates
of Ed of atropine, pilocarpine, or noradrenaline have been
made, previous ex vivo studies demonstrate that delivery of
molecules between 150 and 300 Da molecular weight is
greater than 40% using the 5 kDA membrane perfused at
3–5 ml minute1 (Clough, 2005).
Measurements of sweating rate at baseline over the
microdialysis probes, and at control and EMLA-treated
uninstrumented sites, confirm that neither pretreatment with
topical local anesthetic cream nor probe insertion signifi-
cantly affects basal TEWL (Namer et al., 2004). These data
also suggest that the transient increase in TEWL seen over the
first 20–30 minutes of probe perfusion is most probably a
result of a reduction in the barrier properties of the skin
following application of the EMLA cream used for probe
insertion rather than an increased sweating consequent to the
start of perfusion of the probes. The data from the Ringer-
perfused probes further show that, following the initial
transient effect on TEWL as perfusion commenced, there
was little change in basal sweating during the course of the
study. All sites were equilibrated for approximately 15 min-
utes before the start of perfusion. This is shorter than we have
previously allowed for recovery from the initial trauma of
probe insertion and thus it might be expected that blood flow
in the vicinity of the probe would remain raised for some
time after the start of perfusion (Clough, 1999). However, the
values of TEWL at instrumented sites that we report are
similar to those we measured in uninstrumented skin and to
those previously reported by Bickel et al. (2002, 2004) in
healthy volunteers and in patients with familial dysautonomia
in whom microdialysis probes had been inserted without
local anesthesia. These observations suggest that any inser-
tion induced increase in superficial blood flux did not impact
significantly on the chemically induced sweating that we
subsequently went on to investigate. Further, all of our studies
were carried out in a thermoneutral environment as it has
been shown that sweat glands show maximal cholinergic
sensitivity at normal skin temperature (Shastry et al., 2000;
DiPasquale et al., 2003) and to minimized changes in local
blood flow in the skin.
In summary, we have shown that continuous delivery of
the muscarinic agonist pilocarpine to the skin results in a
directly mediated and sustained sweating that was sensitive
to atropine blockade. This study has, for the first time,
provided information about sweat gland activity with
prolonged stimulation within the same individual using both
cholinergic and adrenergic agonists. We have further shown
that combined delivery of agonists and antagonists via the
microdialysis probe provides an important tool with which to
address the underlying pathologies of sweat gland dysfunc-
tion. In time this technique may be used to investigate and
clarify the complex irregularities that underlie sweat gland
dysfunction.
MATERIALS AND METHODS
Study group
Twenty-one healthy volunteers (11 females and 10 males) were
recruited (age range 23–48; median 28 years). All volunteers gave
written informed consent. The study was approved by the South and
West Research Ethics Committee (ref 265/98) and was conducted
according to the Declaration of Helsinki Principles. All volunteers
were requested to refrain from exercise and caffeine-containing
drinks on the day of study. None were taking any medication nor
had applied moisturizing creams or other topical agents to either arm
for at least 24 hours before the study.
Drugs
Noradrenaline (Levophed, Sanofi Winthrop, UK), pilocarpine nitrate
(Mandeville Medicines, Stoke Mandeville Hospital, UK), lidocaine/
prilocaine (5% EMLA cream, Astra Pharmaceuticals Ltd, Macctes-
field, UK), Ringer’s intravenous solution (Baxter Healthcare Ltd,
Newbury, UK), atropine sulfate (Aurum Pharmaceuticals, Brent-
wood, UK), were obtained from the hospital pharmacy.
Microdialysis probes
Drugs were delivered using linear microdialysis membranes of 2 kDa
molecular mass cutoff, 216 mm outer diameter, 8mm wall thickness
(Gambro model GFE 18, Gambro Dialysaten AG, Hechingen,
Germany). The membranes were glued into a short length of Portex
tubing (0.28 mm internal diameter, 0.61 mm outer diameter) and
a 0.1 mm diameter, 5 cm long stainless-steel wire (Goodfellow
Cambridge Ltd, Cambridge, UK) inserted into each fiber to
strengthen the membrane. Probes were sterilized with ethylene
oxide before use. Once inserted (see below) the probes were
connected via flexible tubing (length 200 cm, volume 1.5 ml; Alaris
Medical Systems, Basingstoke, UK) to 10 ml syringes (Terumo Europe
N.V, 3001 Leuven, Belgium) and perfused at a rate of 5 ml minute1
using a syringe pump (P3000 IVAC Medical Systems, Hants, UK).
Study protocol
All studies were performed in a clinical setting at an ambient
temperature of 221C (721C), with the volunteer lying supine
throughout. Up to six sites on the volar surface of the non-dominant
forearm were anesthetized with EMLA cream under occlusion for
90 minutes. Following removal of the EMLA, a microdialysis probe
was introduced into the dermis at each site to run parallel to the
epidermal surface for a length of 25 mm using a 23-gauge guide
needle (0.6 30 mm, Terumo Europe N.V, 3001 Leuven, Belgium).
Probes were separated by at least 20 mm, avoiding the more distal
part of the forearm. On removal of the guide needles, the probes
were connected to the infusion pumps and perfused at a rate of
5ml minute1 using a syringe pump (P3000 IVAC Medical Systems,
Hants, UK). The outflow from each probe was collected to avoid
wetting the skin, which might affect TEWL readings. As sweating has
been shown to be higher at the wrist (Panisset et al., 1992), probe
perfusion was randomized to site in all studies.
Sweating was assessed directly above each microdialysis probe
and at a control area of skin at the same site on the contralateral arm
using a TEWL meter (Tewameter TM 210, Courage & Khazaka, Koln,
Germany). Measurements of TEWL were made for up to 5.5 hours
at 20 minutes intervals, commencing 5 minutes after the start of
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perfusion. A stable value of TEWL was achieved within 90 seconds.
A second study to investigate the effects of application of the EMLA
cream used as an anesthetic for probe insertion were also performed
in a subset of five volunteers in whom values of TEWL were
measured at 10 minutes intervals for up to 2 hours at EMLA-exposed
and control skin.
At the end of the study, probe depth was measured in a subset of
eight volunteers using high-frequency (20 MHz) ultrasound (Der-
mascan C, Cortex Technology, Hadsund, Denmark). Using the 2D B
mode, the wire insert was followed along its length to ensure that its
depth within the dermis was uniform. Three measurements of fiber
depth were taken using the A mode and the average calculated.
Mean probe depth was 1.0270.1 mm (SEM), placing them in close
proximity to the secretory portion of the dermally located eccrine
sweat glands.
Study 1: dose–response of pilocarpine-induced sweating
Six microdialysis probes were inserted into the forearm of eight
volunteers (four males and four females). Five of the probes were
perfused, each with a randomized concentration of pilocarpine
nitrate (5 105 to 0.5 mg ml1) in Ringer’s solution; the remaining
probe was perfused with Ringer’s solution alone. TEWL was
measured every 20 minutes for the 5 hours perfusion period directly
above each probe and from control sites on the contralateral arm.
Arterial blood pressure and pulse were monitored hourly to ensure
that there were no significant systemic effects.
Study 2: effect of atropine on sweating induced by pilocarpine
or noradrenaline
To investigate the differential effects of cholinergic and adrenergic
stimulation on sweating, TEWL was measured in six volunteers
(three males and three females) in response to pilocarpine
(1.66 mg ml1), noradrenaline (0.005 mg ml1), or a combination
of pilocarpine (1.66 mg ml1) and noradrenaline (0.005 mg ml1).
Six probes were inserted per volunteer with randomization of
perfusate (two for each agonist) to probe site. A high concentration of
both pilocarpine nitrate and noradrenaline were used to ensure
maximal effects on sweat gland activity. As before, TEWL measure-
ments were taken every 20 minutes for 5 hours above each probe
and from sites on the contralateral arm as control.
In three further volunteers (one male and two females), the
effect of muscarinic blockade on cholinergic and adrenergic
stimulation on sweating was investigated using pairs of probes
perfused initially with either pilocarpine (1.66 mg ml1) or noradre-
naline (0.005 mg ml1). TEWL readings were taken every 20 minutes
for 2 hours. The perfusate was then switched to one to which
atropine (0.003 mg ml1) had been added, and TEWL readings
continued at 20 minutes intervals for a further 3 hours.
Data handling
Data are presented as mean7SEM for either peak or steady-state
TEWL. Total sweating was estimated as the AUC0–300 minutes of the
TEWL response over the 5 hours probe perfusion. Where two probes
were perfused with the same solution, the mean of the two values
was taken for any individual. All volunteers acted as their own
controls. Data are compared using non-parametric Mann–Whitney
U-test or Wilcoxon’s signed-rank tests or by analysis of variance
using a repeated-measures analysis and Bonferroni’s post hoc test as
appropriate. Differences were regarded as significant at Po0.05.
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